We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New ELISA-Type Immunologic Test Studies Seroprevalence Against SARS-CoV-2

By LabMedica International staff writers
Posted on 10 Feb 2021
A team of researchers has developed an affordable ELISA-type test that makes it possible to detect IgG and IgM antibodies against the SARS-CoV-2 virus from human serum.

The new ELISA-type immunologic test called DIFELISARS to study the seroprevalence against SARS-CoV-2 has been developed by researchers from the Polytechnic University of Valencia (Valencia, Spain) and is currently in the prototype phase. More...
ELISA-type tests have been applied for decades in various fields of biomedical diagnosis, and they stand out due to their high sensitivity and reliability. Furthermore, they make it possible to analyze a high number of samples simultaneously - up to 120 samples in 180 minutes - which validates its suitability for broad population samplings such as seroprevalence studies.

The DIFELISARS test stands out due to its low cost compared to other existing tests on the market, as well as for its high sensitivity and reliability - classic characteristics of ELISA tests. The test provides a colorimetric signal, proportionate to the concentration of said antibodies, and makes it possible to characterize the sample by comparing positive and negative tests.

The researchers will now validate the test by analyzing a total 200 samples and will also study the differences in the immune response generated - antibody levels - among men and women from the analyzed serum samples. In the study, the team has already started gathering, preparing and characterizing approximately 50 serum samples from patients, which will be used as positive and negative COVID-19 tests. The samples taken will be increased until reaching the 200 needed to conduct the seroprevalence studies.

“The availability of a test of these attributes has now acquired critical importance, as it would allow easy, reliable and cheap monitoring of the individual response of each person during the current vaccination campaign,” said Ángel Montoya, director of the Immunotechnology line of the Ci2B at the Polytechnic University of Valencia.

“Although some ELISAs are currently on sale to detect antibodies against SARS-CoV-2 in human blood products, their price remains high and their real availability is scarce, because large amounts of institutions and governments around the world are trying to acquire them simultaneously in order to conduct their COVID-19 monitoring programs,” added Montoya. “We have worked on this project to tackle this, to get this low-cost test based on existing commercial immunoreactive products ready, which would help facilitate viral seroprevalence studies, while differentiating between sexes, in our immediate surroundings.”

Related Links:
Polytechnic University of Valencia


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
New
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.